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DObjective: The Saphenous Vein Versus Right Internal Thoracic Artery as a Y-Composite Graft (SAVE RITA)
trial was designed to evaluate the noninferiority of the saphenous vein (SV) compared with the right internal
thoracic artery ([R]ITA) used as a Y-composite graft.
Methods:A total of 224 patients who had undergone off-pump revascularization for multivessel coronary artery
disease using the SVor RITA as a Y-composite graft based on the in situ left ITAwere assigned randomly to the
SV Y-composite graft (SV group, n¼ 112) or free RITAY-composite graft (RITA group, n¼ 112). The primary
endpoint was the 1-year angiographic patency rate of the second limb conduits (SV or RITA). Postoperative
1-year coronary angiograms were performed in 215 patients (SV group, 108; RITA group, 107).
Results: The overall graft patency rate was 97.4% (745 of 765) at 1 year (97.9% in the SV group vs 96.9% in
the RITA group, P ¼ .362). The primary endpoint of the study, the 1-year patency rate of the SV composite
grafts, was 97.1% (238 of 245) and was noninferior to that of the RITA composite grafts (97.1% [198 of
204]) with a 95% lower confidence limit of 2.6% (P<.001 for noninferiority). The graft qualities, evaluated
using the FitzGibbon patency grades, were also similar between the 2 groups (P¼ .948). No statistically signif-
icant differences were found in the overall survival rates between the 2 groups at 1 and 4 years (P¼ .998). Also,
no statistically significant differences were found between the 2 groups in the freedom from major adverse car-
diac and cerebrovascular event rates at 1 and 4 years (P ¼ .597).
Conclusions: The SV composite grafts were noninferior to the RITA composite grafts in terms of the 1-year
angiographic patency rates. (J Thorac Cardiovasc Surg 2014;148:901-8)Although the saphenous vein (SV) is still a widely used
conduit for coronary artery bypass grafting (CABG), lower
long-term patency rates and worse clinical outcomes have
been reported after CABG performed with SV aortocoro-
nary grafts compared with CABG performed with internal
thoracic artery (ITA) grafts.1,2 Because the lower patency
rates of SV grafts result from the structural and functional
differences between veins and arteries,3 various efforts
have been made to overcome those limitations.4-6 A
minimal manipulation technique in harvesting the SV has
recently been re-emphasized owing to its benefit in preser-
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The Journal of Thoracic and Cathe minimally manipulated SV as a composite graft based
on the in situ left ITA have been hypothesized to be less
exposure of the SV to direct pressure and circulatory
stress from the ascending aorta and continuous exposure
to the nitric oxide released from the in situ ITA.8-10
The Saphenous Vein Versus Right Internal Thoracic Ar-
tery as a Y-Composite Graft (SAVE RITA) trial is the first
randomized, controlled, clinical trial designed to evaluate
the noninferiority of the SV compared with the right ITA
(RITA) as a Y-composite graft based on the in situ left
ITA. Earlier in the trial, we had demonstrated that SV com-
posite grafts were comparable to RITA composite grafts in
terms of early postoperative angiographic graft patency
and clinical outcomes.11We have since analyzed the primary
endpoint of the trial, the 1-year patency rates of the SV and
RITA composite grafts, and the midterm clinical outcomes.METHODS
The SAVE RITA trial was a randomized, controlled, open-label clinical
trial. The institutional review board (approval no. H-0803-024-237)
approved the study protocol, and all study patients provided informed con-
sent (ClinicalTrials.gov identifier: NCT01051986).
Study Design
The study design and inclusion criteria have been previously described.11
Patients, aged 40 to 75 years, who were scheduled to undergo off-pumprdiovascular Surgery c Volume 148, Number 3 901
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
ITA ¼ internal thoracic artery
MACCE ¼ major adverse cardiac and
cerebrovascular events
OPCAB ¼ off-pump CABG
RITA ¼ right ITA
SAVE RITA ¼ Saphenous Vein Versus Right
Internal Thoracic Artery as a
Y-Composite Graft
SV ¼ saphenous vein
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DCABG(OPCAB) formultivessel coronary arterydisease using aY-composite
graft based on the in situ left ITAwere evaluated for eligibility. The exclusion
criteria included ineligible Y-composite graft revascularization, an
unavailable RITA or SV, left ventricular dysfunction (ejection fraction
 25%), chronic renal failure requiring renal replacement therapy, previous
cardiac surgery, emergency operation, or a medical history such asmalignant
disease that might limit the possibility of midterm follow-up. The primary
endpoint measurement of the SAVE RITA trial was the 1-year angiographic
patency rate of the second limb conduits (SV or RITA). The secondary
endpoint measurements were the early postoperative angiographic patency
rate of the conduits and midterm clinical outcomes, including overall
survival and rates of freedom from cardiac death and major adverse cardiac
and cerebrovascular events (MACCE).
Of 511 patients who had undergone first-time isolated CABG from
September 2008 to October 2011, the 496 patients scheduled to undergo
OPCAB were assessed for eligibility by 1 of us (K-B.K.). The 224
eligible patients who were expected to receive an in situ left ITA-based
Y-composite graft for complete revascularization (mean age, 62.7  7.8
years) were assigned randomly to 1 of the 2 study groups in a 1:1
manner, depending on the second limb conduit used for construction of the
Y-composite graft: the SV Y-composite graft (SV group, n ¼ 112) or the
free RITA Y-composite graft (RITA group, n ¼ 112). Randomization was
performed intraoperatively using a web-based block randomization method,
controlled by themedical research collaboration center at our institution,with
randomly determined block sizes of 4 and 6. The preoperative characteristics
and risk factors, including age (SV vs RITA group, 63.3 7.8 vs 62.8 8.0
years, P ¼ .647), hypertension (80 [71.4%] vs 76 [67.9%], P ¼ .561),
diabetes (47 [42.0%] vs 51 [45.5%], P ¼ .590), and 3-vessel disease
(90 [80.4%] vs 87 [77.7%], P¼ .623) were mostly similar and comparable
between the 2 groups (Table 1). Of the 224 patients, 9 (4.0%) were excluded
from the 1-year postoperative angiographic evaluation; 5 patients (2.2%)
were withdrawn because of intraoperative protocol violations, 1 patient
died in the early postoperative period, and 3 patients refused to undergo the
1-year angiographic follow-up examination. The 1-year (12.6 2.0 months)
angiographic graft patency rates were evaluated in 215 patients (98.6%; SV
group, 108;RITAgroup, 107) of the 218 patientswho hadundergoneOPCAB
as planned and had survived (Figure 1).
Operative Strategies
The basic surgical procedures and principles of OPCAB have been pre-
viously described.7,11
The left and right ITAs were both harvested using a skeletonization
technique. The greater SV was harvested from a lower leg after systemic
heparinization. The manipulation and tension of the SV were minimized
during harvest, and manual intraluminal dilatation was avoided. Immedi-
ately after the second limb conduit (SV or RITA) was harvested, it was
anastomosed to the side of the left ITA without any pharmacologic902 The Journal of Thoracic and Cardiovascular Surgtreatment. After the Y-composite graft had been constructed, the distal
end of the second limb conduit was clamped with an atraumatic bulldog
clamp. The left anterior descending coronary artery territory was revascu-
larized first, using the left ITA, and the second limb conduit was left to be
dilated spontaneously by the native flow and pressure of the left ITA. The
left circumflex coronary artery territory was then revascularized, followed
by the right coronary artery territory. A sequential anastomotic technique
was used when>2 coronary arterial anastomoses were needed. When the
length of 1 or both limb conduits of the Y graft was not sufficient to reach
the target vessels, an additional SV segment from the other lower leg (the
third limb conduit) was harvested to lengthen the graft limb in an I-shape.
The average number of distal anastomoses per patient (SV vs RITA group,
3.5  0.9 vs 3.6  0.8, P ¼ .769) and per the left ITA (SV vs RITA group,
1.2  0.5 vs 1.2  0.5, P ¼ .585) was similar between the 2 groups. The
number of distal anastomoses in the 3 coronary artery territories was
also similar between the 2 groups, as reported in our earlier analysis.11
However, the number of distal anastomoses using the second limb conduit
was smaller in the RITA group than in the SV group (1.9 0.7 vs 2.3 0.8,
P<.001), and the third limb conduit to lengthen the graft limb was needed
more frequently in the RITA group than in the SV group (n ¼ 40 vs n ¼ 4,
P<.001).
The patients were given an initial dose of heparin (1.5 mg/kg) and peri-
odic supplemental doses to maintain an activated clotting time of>300 sec-
onds. All patients took aspirin until the day of surgery and resumed it as
soon as possible after surgery, usually at 1 day postoperatively. If the pa-
tient had a high blood level of low-density lipoprotein cholesterol (>100
mg/dL) postoperatively, drug therapy was initiated.
Evaluation of Endpoints
The graft patency was graded in the manner described by FitzGibbon
and colleagues.12 Grades A (excellent) and B (fair) were treated as patent.
Grade O anastomosis, which included stenosis of 75% of the vessel
diameter or a totally occluded graft, was treated as occluded. One physi-
cian, who was unaware of this clinical trial, initially reviewed all the cor-
onary angiograms, and consensus was reached after review. The patients
underwent regular postoperative follow-up examinations through the
outpatient clinic at 2- or 3-month intervals and were interviewed by tele-
phone for confirmation of their condition if the last clinic visit had not
been conducted at the scheduled point. The clinical and angiographic
follow-up examinations were completed on December 31, 2012. The
follow-up data were complete for all survivors, with a median follow-up
duration of 34 months (range, 4 to 52). Cardiac death was defined as any
death related to cardiac events, including sudden death during the
follow-up period. The MACCE included cardiac death, angina recurrence,
ST-segment elevation and non–ST-segment elevation myocardial infarc-
tion, coronary reintervention (including redo-CABG), and cerebrovascular
accident (defined as new and sudden-onset neurologic deficits lasting>24
hours with no apparent nonvascular causes).
Statistical Analysis
The study was designed to have 80% power with a 1-sided type I error
of 5% and a noninferiority margin of8%. The 1-year patency rates were
expected to be 93% in the SVand 95% in the RITA grafts. A total of 194
anastomoses using the second limb conduit were required in each group.
Because no correlation was assumed between the distal anastomoses in
each patient, 97 patients in each group were needed to complete the study
cohort when using an estimated average number of 2 distal anastomoses per
conduit. Allowing for a 3%withdrawal rate in the perioperative period and
10% during 1-year follow-up period, it was calculated that 112 patients
would be needed in each group.
Statistical analysis was performed using the Statistical Package for So-
cial Sciences software package, version 12.0 (SPSS, Inc, Chicago, Ill).
Data are expressed as the mean  standard deviation or proportions. Theery c September 2014
TABLE 1. Baseline demographic data and risk factors
Variable
SV group
(n ¼ 112)
RITA group
(n ¼ 112) P value
Age (y) 63.3  7.8 62.8  8.0 .647
Female gender 30 (26.8) 21 (18.8) .152
Risk factors
Smoking 57 (50.9) 53 (47.3) .593
Hypertension 80 (71.4) 76 (67.9) .561
Diabetes mellitus 47 (42.0) 51 (45.5) .590
Dyslipidemia 19 (17.0) 14 (12.5) .346
Overweight (BMI  25 kg/m2) 51 (45.5) 51 (45.5) >.999
History of stroke 13 (11.6) 18 (16.1) .333
Unstable angina 83 (74.1) 84 (75.0) .878
Left main disease 41 (36.6) 43 (38.4) .783
Three-vessel disease 90 (80.4) 87 (77.7) .623
Logistic EuroSCORE (%) 3.2  2.5 3.3  2.7 .710
LVEF (%) 58.0  9.7 56.2  9.2 .172
BMI, Body mass index; EuroSCORE, European system for cardiac operative risk
evaluation; LVEF, left ventricular ejection fraction; SV, saphenous vein; RITA, right
internal thoracic artery.
Kim et al Acquired Cardiovascular Diseaseunit of analysis was an anastomosis, under the assumption that each anas-
tomosis would be independent from each other in each patient. Compari-
sons between the 2 groups were made using the chi-square test andFIGURE 1. Summary flow diagram of participants. ITA, Internal thoracic artery;
The Journal of Thoracic and CaFisher’s exact test for categorical variables and the Student t test for contin-
uous variables. The time-to-event outcomes were analyzed using Kaplan-
Meier survival curves, and comparisons between the 2 groups were
performed using the log-rank test. The primary endpoint was analyzed as
the proportion of difference with the 95% 1-sided confidence interval, to
test for the noninferiority hypothesis. The P value was calculated using a
z-test method. The null hypothesis was that the SV graft was inferior to
the RITA graft based on the 1-year angiographic patency rate, with a non-
inferiority margin of8%. The clinical outcomes were analyzed using the
‘‘intention-to-treat’’ approach in all 224 study patients. The angiographic
patency rates were compared using a ‘‘per-protocol’’ analysis in 215 pa-
tients, because the endpoint was the patency rate of the distal anastomoses
using the second limb conduit.RESULTS
One-Year Postoperative Angiographic Results
In the 215 patients (108 in the SV group; 107 in the RITA
group), who were evaluated using the 1-year angiograms,
the overall graft patency rate was 97.4% (745 of 765) at 1
year postoperatively (97.9% [375 of 383] in the SV group
vs 96.9% [370 of 382] in the RITA group; P ¼ .362;
Figure 2). The 1-year patency rate of the distal anastomoses
using the second limb conduit was 97.1% (238 of 245) inSV, saphenous vein; LVEF, left ventricular ejection fraction; RITA, right ITA.
rdiovascular Surgery c Volume 148, Number 3 903
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FIGURE 2. Patent saphenous vein (SV) Y-composite grafts based on the in situ left internal thoracic artery (LITA) on (A) early postoperative and (B) 1-year
angiograms in a 74-year-old male patient. The in situ LITAwas anastomosed to the left anterior descending coronary artery (white arrow), and the SV was
anastomosed to the obtuse marginal coronary artery (black arrowhead) and right posterolateral coronary artery (black arrow) using a sequential anastomotic
technique.
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difference that was 0% within the 95% 1-sided confidence
interval of 2.6% to N. The lower confidence limit was
greater than the noninferiority margin (8%), with
P<.001 for the test of noninferiority in the 1-year patency
rate of the SV to the RITA (Table 2). When the second limb
conduit patency rates were compared according to the target
coronary artery territories, no statistically significant differ-
ences were found in the patency rates between the 2 groups,
although the SV group showed a trend toward a lower
patency rate in the right coronary artery territory than in
the other coronary territories (P ¼ .082; Table 3). One
SV composite graft showed stenosis of 50% at the
Y-anastomosis site at 1 year postoperatively, although it
was widely patent on the early postoperative angiogram.
Comparison of Anastomotic Qualities
When the graft patency grades were evaluated in the
manner described by FitzGibbon and colleagues,12 the pro-
portion of grade A, B, and O of the in situ left ITA grafts at 1
year was not statistically different between the 2 groups.
Those of the second limb conduits were also not statistically
different between the 2 groups at 1 year postoperatively
(Table 4).TABLE 2. One-year angiographic patency rates of distal anastomoses
Variable Total (n ¼ 215) SV gr
Overall grafts 745/765 (97.4) 375
Grafts using LITA 263/263 (100) 134
Grafts using second conduit 436/449 (97.1) 238
Grafts using third conduit 46/53 (86.8)
Data presented as n/total (%). SV, Saphenous vein; RITA, right internal thoracic artery; LIT
using z-test for noninferiority. zP value using Fisher’s exact test for inequality.
904 The Journal of Thoracic and Cardiovascular SurgOverall and Cardiac Death–Free Survival Rates
One operative death occurred in the RITA group. Of the
223 survivors, late death occurred in 3 (1.3%); 2 in the SV
group (1 cardiac death and 1 pneumonia) and 1 death from
malignancy in the RITA group. The overall survival rate at 1
and 4 years was 99.6% and 97.7%, respectively, without a
statistically significant difference (P ¼ .998). The freedom
from cardiac death rate was not compared between the 2
groups because only 1 event occurred during the follow-
up period.
Freedom From MACCE
During the study period, 12 patients (4 in the SV group; 8
in the RITA group) experienced angina recurrence. Percuta-
neous coronary intervention was performed in 4 patients in
the RITA group. The indications for percutaneous interven-
tion were occlusion of the left ITA graft in 1, occlusion of
the RITA graft in 1, and progression of the native coronary
artery disease in 2. Redo-CABG was performed in 1 patient
in the SV group at 21 months postoperatively. Although the
bypass grafts were all patent, progression of native coronary
artery disease created the need for reoperation. The freedom
from reintervention rate at 1 and 4 years postoperatively
was 100% and 98.5%, respectively, without a statisticallyoup (n ¼ 108) RITA group (n ¼ 107) P value
/383 (97.9) 370/382 (96.9) .362*
/134 (100) 129/129 (100) —
/245 (97.1) 198/204 (97.1) <.001y
3/4 (75.0) 43/49 (87.8) .443z
A, left internal thoracic artery. *P value using chi square test for inequality. yP value
ery c September 2014
TABLE 3. Comparison of 1-year patency rates for distal anastomoses
performed with second limb conduits between saphenous veins and
right internal thoracic arteries according to coronary artery
territories
Variable SV group (n ¼ 108) RITA group (n ¼ 107) P value
Total 238/245 (97.1) 198/204 (97.1) .958
LAD territory 46/47 (97.9) 42/42 (100) >.999
LCX territory 121/122 (99.2) 115/119 (96.6) .209
RCA territory 71/76 (93.4) 41/43 (95.3) >.999
P value .082 .207 —
Data presented as n/total (%). SV, Saphenous graft; RITA, right internal thoracic ar-
tery; LAD, left anterior descending coronary artery; LCX, left circumflex artery;
RCA, right coronary artery.
FIGURE 3. Comparison of freedom from major adverse cardiac and ce-
rebrovascular events (MACCE) between the saphenous vein (SV) and right
internal thoracic artery (RITA) groups.
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98.9% in the SV group vs 99.1% and 95.3% in the RITA
group, P ¼ .177). Two patients experienced stroke events,
35 and 48 months after surgery. None of the patients expe-
rienced acute myocardial infarction. The freedom from
MACCE rate at 1 and 4 years postoperatively was 97.8%
and 92.8%, respectively, without a statistically significant
difference between the 2 groups (97.3% and 94.4% in the
SV group vs 98.2% and 91.1% in the RITA group,
P ¼ .597; Figure 3). The freedom from the composite end-
points of 1-year graft occlusion and MACCE at 1 and 4
years postoperatively was also similar between the 2 groups
(89.3% and 87.2% in the SV group vs 89.2% and 83.2% in
the RITA group, P ¼ .594).DISCUSSION
The SAVE RITA trial revealed 2 main findings. First, the
1-year angiographic patency rate of the SVused as a Y-com-
posite graft based on the in situ left ITAwas noninferior to
that of the RITA composite graft. Second, the clinical re-
sults of OPCAB using SV composite grafts showed no sta-
tistically significant difference compared with those of
OPCAB using the RITA composite grafts up to 4 years afterTABLE 4. Comparison of anastomotic qualities between SVand RITA
groups on 1-year angiograms
Conduit
FitzGibbon
grade
SV group
(n ¼ 108)
RITA group
(n ¼ 107) P value
LITA .440
A 132/134 (98.5) 125/129 (97.0)
B 2/134 (1.5) 4/129 (3.0)
O 0/134 (0) 0/129 (0)
Second limb
conduit
(SVor RITA)
.948
A 232/245 (94.7) 192/204 (94.1)
B 6/245 (2.4) 6/204 (2.9)
O 7/245 (2.9) 6/204 (2.9)
SV, Saphenous vein; RITA, right internal thoracic artery; LITA, left internal thoracic
artery.
The Journal of Thoracic and Casurgery in terms of overall survival and MACCE-free sur-
vival rates.
Poor long-term patency rates and clinical outcomes have
been reported after CABG performed with SV aortocoro-
nary grafts compared with CABG performed with ITA
grafts.1,2,13,14 From the experience using left ITA grafts,
arterial grafts have been thought to be better conduits than
SV grafts, and many trials have compared the patency
rates of the radial artery and SV, with conflicting
results.15,16 In contrast, the RITA has been considered a
second conduit of choice after the left ITA, because of its
freedom from atherosclerotic changes, excellent long-
term patency, and improved long-term survival rate.17,18
The SAVE RITA trial is the first randomized, controlled,
open-label clinical trial designed to evaluate the SV
compared with the RITA as a second limb conduit anasto-
mosed to the side of the in situ left ITA. Our noninferiority
hypothesis was developed from the improved SV patency
rates reported in recent studies.5,19,20 In our previous
retrospective study,19 we demonstrated that the 1-year
patency rate of the SV composite grafts was 92.1%, similar
to the patency rate of arterial composite grafts using the
RITA and right gastroepiploic artery (91.0%). From these
results, the 1-year patency rate of the SV composite graft
was estimated as 93% in the present trial. Similarly, the
1-year patency rate of the RITA composite graft was esti-
mated as 95% from our previous study, demonstrating
94.0% and 94.1% patency rates of the RITA grafted to
the left circumflex and right coronary artery territories,
respectively.21rdiovascular Surgery c Volume 148, Number 3 905
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explain the propensity of SV grafts to undergo relatively
early occlusion compared with ITA grafts.1 Of the various
processes known to mediate SV graft occlusion, vessel
wall injury, which results from mechanical trauma and/or
exposure to arterial pressure, is regarded as a key factor.
Numerous efforts to preserve the structure and function of
the venous endothelium, including technical modifications
of SV harvesting, rigorous application of secondary preven-
tion methods, and modification of lifestyle factors, have
been made to overcome the limitations of SV grafts.7,22,23
However, recent trials have still demonstrated
unsatisfactory patency rates for the SV (89% at 1 year and
81.4% at 5 years) harvested with conventional methods and
used as aortocoronary bypass grafts.16,24 In the SAVE RITA
trial, the SV tension was minimized during harvest, and
manual intraluminal dilatation was avoided. In addition, we
used the SV as a second limb conduit to construct the
Y-composite graft. The theoretical advantages of using the
SV as a Y-composite graft over an aortocoronary bypass
graft include that the SV conduit anastomosed to the side of
the left ITA is exposed to less circulatory stress than a
conduit anastomosed to the ascending aorta; that the SV
composite graft is exposed continuously to endothelium-
protective substances such as nitric oxide produced from
the left ITA8,11; and that complications such as embolic
stroke and aortic dissection could be reduced by avoiding
aortic clamping for proximal anastomosis. The additional
benefits of using SV composite grafts compared with
bilateral ITA composite grafts are that the RITA, the second
conduit of choice after the left ITA, is reserved for later
redo CABG; that the risk of perioperative morbidity, such
as sternal infection, which can occur after bilateral ITA use,
is decreased; and that the length of the SV is preserved
compared with aortocoronary SV grafts, because the SV
from a unilateral lower leg will be enough for complete
revascularization in most patients with multivessel coronary
artery diseasewhenusing a sequential anastomotic technique.
In the early results of the SAVE RITA trial, we demon-
strated that SV composite grafts were comparable to
RITA composite grafts in terms of early angiographic
patency and postoperative clinical outcomes (1 in-hospital
mortality in the RITA group; 1 mediastinitis in the SV
group).11 The patency rates of the SV composite grafts in
the SV group showed no statistically significant differences
compared with the patency rates of the RITA composite
grafts in the RITA group (98.8% [245 of 248] vs 99.5%
[207 of 208]; P ¼ .629). The trial results demonstrated
that the 1-year angiographic patency of the SV composite
graft was noninferior to that of the RITA composite graft.
The difference was 0%, and the lower margin of the confi-
dence interval was2.6%, a sufficiently smaller difference
than the prespecified noninferiority margin of 8% to
reject the null hypothesis. The SV grafted on the right906 The Journal of Thoracic and Cardiovascular Surgcoronary artery territory showed a lower patency rate than
that grafted on the left coronary artery territory, but the dif-
ference was not statistically significant. Although we did
not evaluate factors, such as the minimum coronary artery
lumen diameter and maximal coronary artery stenosis, a
large diameter of the right coronary artery with a moderate
degree of stenosis might cause a lower patency rate in the
right coronary artery territory. Another possible explanation
is that revascularization of the right coronary artery territory
using an SV composite graft needs a longer SV graft with
valves inside, which could cause blood stasis and thrombus
formation, particularly in situations causing competitive
flow. This requires additional investigation.
The differences in the midterm clinical outcomes,
including overall survival and freedom from cardiac death,
and freedom from MACCE, were also not statistically sig-
nificant between the 2 groups.Study Limitations
The present study had limitations that must be recog-
nized. First, the present study was not a multicenter ‘‘all-
comers’’ study, although it was a prospective, randomized,
controlled trial. The study should be performed as a
multicenter-based trial to overcome the institutional factor.
Second, the 1-year graft patency rates and clinical outcomes
with a median follow-up duration of 34 months did not pro-
vide sufficient data to reach a definite conclusion on the
noninferiority of the SV composite graft compared with
the RITA composite graft. It will be necessary to extend
our patency study up to several years after surgery and
analyze the long-term clinical outcomes to demonstrate
that the advantages of SV composite grafting are sufficient
to overcome the previously published advantages of the
RITA over the SV as an additional conduit.References
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Dr Sary F. Aranki (Boston, Mass). I have nothing to disclose.
This is the fourth study in this meeting that addresses the theme of
more arterial revascularization and the use of bilateral internal
mammary arteries in patients undergoing CABG surgery.
Dr Kim and his colleagues just presented the only study that was
a randomized controlled study. They previously published
graft patency rates at 1 day. Now, they present the 1-yearThe Journal of Thoracic and Caangiographic data for 98% of their randomized patients. In addi-
tion, they also report on the 1- and 4-year clinical outcomes.
Their major findings were that if the SV graft is used as a Y-
composite graft from the left internal mammary artery (LIMA),
it is as good, or noninferior, as a free RIMA graft deployed in
the same fashion regarding the 1-year patency and 1- and 4-year
outcomes. Therefore, I interpret these results to indicate that a
SV graft from the LIMA is as good as a bilateral internal mammary
artery. These results are too good to be true. However, I congratu-
late Dr Kim and his team on a study well done and a well-written
and clear report.
Dr Kim, I am very nervous every time I use the LIMA as the sole
source of coronary blood supply in patients with 3-vessel disease. I
believe that the LIMA is so valuable that it should be used prefer-
entially for the left anterior descending artery; no sharing. Howev-
er, the results speak for themselves. I have the following questions
for you.
Question 1. How do you determine preoperatively and intrao-
peratively whether the LIMA is going to have adequate blood
flow to sustain the entire coronary circulation?
Dr Kim. Thank you, Sary, for your nice comments and good
questions. We have performed CABG using a Y-composite graft
based on the left ITA single inflow in most of our patients
since mid-2000. Although a concern exists that construction of a
Y-composite graft based on the left ITA single inflow may not
supply sufficient blood flow to a wider area of myocardium, we
are not able to decide it preoperatively or intraoperatively.
In our previous study, we compared the degree and time course
of myocardial perfusion improvement between the bilateral in situ
ITAs group and the Y-composite group using the myocardial single
photon emission computed tomography performed preoperatively
and at 3 months and 1 year after surgery. We published the data in
the Journal of Thoracic and Cardiovascular Surgery in 2007. Our
data demonstrated that revascularization with a Y-composite graft
or bilateral in situ ITAs graft exhibited a complete recovery of
stress perfusion and a similar pattern of reversibility improvement
until 1 year after surgery. Therefore, we suggest that revasculariza-
tion using a Y-composite graft based on the left ITA single inflow
might be sufficient to supply the whole heart.
Dr Aranki. Okay. My second question. There were 245 distal
anastomoses with the vein graft versus 204 in the RITA group.
Was this difference significant and did those patients have more
complete revascularization?
Dr Kim. As I presented in my slides, the average length of the
harvested RITA was shorter than that of the SV harvested from a
lower leg. Therefore, the average number of distal anastomoses us-
ing the RITAwas smaller than that of distal anastomoses using the
SV. When the length of the Y-composite graft was not sufficient for
complete revascularization, an additional SV segment was harvested
to lengthen the conduit. In the RITA group, an additional SV
segment was harvested in 40 patients and connected to the RITA
for complete revascularization. Therefore, the average number of
distal anastomoses per patient was similar between the 2 groups.
DrAranki. The next question, and the last. Currently, only 20%
of coronary bypass operations are done as OPCAB in the United
States. What would your advice be to surgeons who perform on-
pump CABG? Do you advise them to do a Y-vein graft to the
LIMA in those patients, too, or just for OPCAB patients?rdiovascular Surgery c Volume 148, Number 3 907
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DDrKim.My answer is yes. We also performed on-pump CABG
using the SV composite graft. I would like to recommend using the
SV composite graft for both off-pump and on-pump CABGs.
There are several advantages using the SV composite graft over
the aortocoronary bypass graft.
First, the SV conduit may be exposed to less circulatory stress
than a conduit anastomosed to the ascending aorta. Second, the
SV conduit anastomosed to the left ITA is exposed continuously
to endothelium-protective substances such as nitric oxide pro-
duced from the ITA. Third, complications such as embolic stroke
and aortic dissection could be reduced by avoiding additional
aortic clamping for proximal anastomosis during on-pump CABG.
Dr Aranki. Thank you, Dr Kim.
Dr John D. Puskas (New York, NY). No disclosures. Dr Kim, I
am impressed with your study. I congratulate you and your col-
leagues for excellent surgical results and the rigor to embark and
complete a prospective randomized trial; I know how difficult that is.
I was also impressed by your answers and your thoughts of why
the vein might actually do so well coming off the ITA. There might
be another possible explanation. I noticed that you chose the lower
leg vein, which would naturally be smaller in caliber than the upper
thigh vein and would match your ITA somewhat better. You also
harvested that vein using an open technique with minimal manipu-
lation. I think it is very important, in general, how we harvest our
conduits and that they be harvested in an atraumatic way; whether
opened or closed, they should be atraumatically harvested.
Do you think that might be 1 reason in this short follow-up, the
vein was performing as well as a RITA? Is it the harvest technique
you used for the vein that improves its function and makes it
perform similar to an RITA?
Dr Kim. Whenever harvesting the SV, it is very important to
prevent inadvertent SV injury. It might be one of the factors for
our improving patency results with SV composite grafting.
Dr Puskas.Doyou dilate the veins under pressurewith a syringe?
Dr Kim.No, we do not manually dilate the SVafter harvesting.
The SV harvest was initiated after systemic heparinization. It was
performed using an atraumatic, open technique, so that manipula-
tion was limited to the perivascular tissue, leaving the surrounding
adipose tissue in place. Immediately after the SV was harvested, it
was used to construct a Y-composite graft.908 The Journal of Thoracic and Cardiovascular SurgDr Puskas. I agree with all of those points. How do you
construct your anastomosis between the lower leg atraumatically
harvested SV and the ITA? Do you make a T or a Y?
Dr Kim. I always perform a Y-anastomosis using an 8-0 poly-
propylene continuous suture technique.
Dr Puskas. Congratulations on your study.
Dr Brian F. Buxton (Melbourne, Australia). I think this is an
excellent study, and I do not know of any or very few other ran-
domized trials comparing the RITA with the SV, with exception
of only one other.
Now the question is, when I first had the privilege of being
a primary discussant with your study, I think it was 2 years
ago, I wondered why at the time you chose to use an off-
pump technique rather than conventional anastomoses from
the aorta. However, having looked at the brilliant results that
you have had with Y-grafting and off-pump surgery, I now fully
understand.
The question I really want to ask you is, what are the power cal-
culations? Is 112 patients in each group enough to give you a long-
term result?
Dr Kim. We have to extend our patency study up to several
years after surgery and analyze the long-term clinical outcomes.
Dr A. Pieter Kappetein (Rotterdam, The Netherlands). The
other part of the question was did you perform a sample size
calculation?
Dr Kim. The study was designed to have 80% power to detect
1-year patency rates of 93% in the SV versus 95% in the RITA
grafts, with a noninferiority margin of8%. A total of 97 patients
were required in each group.
Allowing for a 3% withdrawal in the perioperative period and a
10% withdrawal during 1 year of follow-up, it was calculated that
recruitment of 112 patients was needed in each group.
Dr Buxton. An inferiority calculation is somewhat difficult,
and this is going to test the statistics of that calculation.
But the other issue is, having been down this road before, look-
ing at the long-term results after changing a technique in coronary
artery bypass surgery, I am still struggling after 10 years, because
the changes are very slow to evolve. Thus, I think 1 year is going to
be the first of a number of study periods, possibly even as long as 5
or 10 years.ery c September 2014
